The estimated Net Worth of Alberto R Jr Martinez is at least $88.2 Thousand dollars as of 28 February 2020. Alberto Martinez owns over 5,000 units of Imunon Inc stock worth over $88,200 and over the last 14 years he sold CLSN stock worth over $0. In addition, he makes $0 as Independent Director at Imunon Inc.
Alberto has made over 33 trades of the Imunon Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of CLSN stock worth $4,500 on 28 February 2020.
The largest trade he's ever made was buying 45,000 units of Imunon Inc stock on 15 February 2017 worth over $9,900. On average, Alberto trades about 6,691 units every 62 days since 2010. As of 28 February 2020 he still owns at least 45,000 units of Imunon Inc stock.
You can see the complete history of Alberto Martinez stock trades at the bottom of the page.
Dr. Alberto R. Martinez, M.D., is Independent Director of Celsion Corporation., since December 6, 2010. He is currently a consultant to the healthcare industry. From 2007 to 2008, Dr. Martinez served as the President and Chief Operating Officer of Talecris Biotherapeutics, Inc., a publicly traded life science company. Prior to that, Dr. Martinez served as Talecris’ President and Chief Executive Officer from October 2005 until June 2007. Prior to that, he held increasingly senior positions as Executive Vice President of Worldwide Commercial Operations at ZLB Behring (subsequently renamed CSL Behring). Prior to ZLB Behring, Dr. Martinez served in various international positions at Sandoz Pharmaceuticals (currently the generic pharmaceuticals division of Novartis) in Brazil, Switzerland, Spain and the U.S. for eighteen years. Dr. Martinez completed his undergraduate and graduate studies at the University of Sao Paulo and received his medical degree from the University of Sao Paulo in 1973. After completing his residency in Pediatrics in 1975, he studied Business and Marketing Administration at the Fundacao Getulio Vargas in Sao Paulo, Brazil.
Alberto Martinez is 65, he's been the Independent Director of Imunon Inc since 2010. There are 2 older and 11 younger executives at Imunon Inc. The oldest executive at Imunon Inc is Michael H. Tardugno, 70, who is the Exec. Chairman, Pres & CEO.
Alberto's mailing address filed with the SEC is C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE, NJ, 08648.
Over the last 17 years, insiders at Imunon Inc have traded over $895,739 worth of Imunon Inc stock and bought 973,579 units worth $2,229,348 . The most active insiders traders include Gary W Pace, Max Link, and Sean F. Moran. On average, Imunon Inc executives and independent directors trade stock every 38 days with the average trade being worth of $22,407. The most recent stock trade was executed by Michael H Tardugno on 12 April 2022, trading 4,000 units of CLSN stock currently worth $14,120.
Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.
Imunon Inc executives and other stock owners filed with the SEC include: